China · Delayed Price · Currency is CNY Luyan Pharma Statistics
Total Valuation
Luyan Pharma has a market cap or net worth of CNY 5.49 billion. The enterprise value is 10.19 billion.
| Market Cap | 5.49B |
| Enterprise Value | 10.19B |
Important Dates
The last earnings date was Tuesday, April 21, 2026.
| Earnings Date | Apr 21, 2026 |
| Ex-Dividend Date | Jul 10, 2025 |
Share Statistics
Luyan Pharma has 388.52 million shares outstanding. The number of shares has decreased by -0.32% in one year.
| Current Share Class | 388.52M |
| Shares Outstanding | 388.52M |
| Shares Change (YoY) | -0.32% |
| Shares Change (QoQ) | -1.16% |
| Owned by Insiders (%) | 3.50% |
| Owned by Institutions (%) | 0.46% |
| Float | 232.41M |
Valuation Ratios
The trailing PE ratio is 19.91.
| PE Ratio | 19.91 |
| Forward PE | n/a |
| PS Ratio | 0.26 |
| PB Ratio | 1.62 |
| P/TBV Ratio | 2.01 |
| P/FCF Ratio | 17.82 |
| P/OCF Ratio | 10.56 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.36, with an EV/FCF ratio of 33.07.
| EV / Earnings | 36.71 |
| EV / Sales | 0.48 |
| EV / EBITDA | 14.36 |
| EV / EBIT | 17.77 |
| EV / FCF | 33.07 |
Financial Position
The company has a current ratio of 1.11, with a Debt / Equity ratio of 1.55.
| Current Ratio | 1.11 |
| Quick Ratio | 0.77 |
| Debt / Equity | 1.55 |
| Debt / EBITDA | 7.38 |
| Debt / FCF | 17.00 |
| Interest Coverage | 3.37 |
Financial Efficiency
Return on equity (ROE) is 8.28% and return on invested capital (ROIC) is 5.39%.
| Return on Equity (ROE) | 8.28% |
| Return on Assets (ROA) | 2.76% |
| Return on Invested Capital (ROIC) | 5.39% |
| Return on Capital Employed (ROCE) | 14.58% |
| Weighted Average Cost of Capital (WACC) | 3.66% |
| Revenue Per Employee | 3.82M |
| Profits Per Employee | 49,535 |
| Employee Count | 5,602 |
| Asset Turnover | 1.65 |
| Inventory Turnover | 7.28 |
Taxes
In the past 12 months, Luyan Pharma has paid 98.61 million in taxes.
| Income Tax | 98.61M |
| Effective Tax Rate | 26.37% |
Stock Price Statistics
The stock price has increased by +74.51% in the last 52 weeks. The beta is 0.11, so Luyan Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.11 |
| 52-Week Price Change | +74.51% |
| 50-Day Moving Average | 14.93 |
| 200-Day Moving Average | 12.50 |
| Relative Strength Index (RSI) | 45.00 |
| Average Volume (20 Days) | 49,843,869 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Luyan Pharma had revenue of CNY 21.42 billion and earned 277.50 million in profits. Earnings per share was 0.71.
| Revenue | 21.42B |
| Gross Profit | 1.49B |
| Operating Income | 573.09M |
| Pretax Income | 373.87M |
| Net Income | 277.50M |
| EBITDA | 647.26M |
| EBIT | 573.09M |
| Earnings Per Share (EPS) | 0.71 |
Balance Sheet
The company has 555.93 million in cash and 5.24 billion in debt, with a net cash position of -4.68 billion or -12.05 per share.
| Cash & Cash Equivalents | 555.93M |
| Total Debt | 5.24B |
| Net Cash | -4.68B |
| Net Cash Per Share | -12.05 |
| Equity (Book Value) | 3.39B |
| Book Value Per Share | 8.69 |
| Working Capital | 1.00B |
Cash Flow
In the last 12 months, operating cash flow was 519.76 million and capital expenditures -211.73 million, giving a free cash flow of 308.03 million.
| Operating Cash Flow | 519.76M |
| Capital Expenditures | -211.73M |
| Depreciation & Amortization | 74.16M |
| Net Borrowing | 79.87M |
| Free Cash Flow | 308.03M |
| FCF Per Share | 0.79 |
Margins
Gross margin is 6.98%, with operating and profit margins of 2.68% and 1.30%.
| Gross Margin | 6.98% |
| Operating Margin | 2.68% |
| Pretax Margin | 1.75% |
| Profit Margin | 1.30% |
| EBITDA Margin | 3.02% |
| EBIT Margin | 2.68% |
| FCF Margin | 1.44% |
Dividends & Yields
This stock pays an annual dividend of 0.35, which amounts to a dividend yield of 2.50%.
| Dividend Per Share | 0.35 |
| Dividend Yield | 2.50% |
| Dividend Growth (YoY) | 16.67% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 112.55% |
| Buyback Yield | 0.32% |
| Shareholder Yield | 2.82% |
| Earnings Yield | 5.05% |
| FCF Yield | 5.61% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 29, 2019. It was a forward split with a ratio of 1.7.
| Last Split Date | May 29, 2019 |
| Split Type | Forward |
| Split Ratio | 1.7 |
Scores
Luyan Pharma has an Altman Z-Score of 2.35 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.35 |
| Piotroski F-Score | 5 |